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Abstract 
Introduction: Carcinomatous meningitis in breast cancer occurs as a complication in up to 
5% of all cases. It is a very devastating diagnosis, with a median patient survival of about 3 
months. Treatment is very controversial, and different modalities of treatment have been 
used but none of them show significant benefit for overall survival. Case Reports: We report 
2 cases of carcinomatous meningitis in breast cancer patients. They received a similar treat-
ment of a combination of intrathecal (IT) methotrexate followed by craniospinal radiothera-
py. Both patients survived for many years after treatment and are in complete clinical and 
radiological remission. Conclusion: Meningeal metastasis from breast cancer can be very 
effectively treated with IT and/or systemic chemotherapy followed by craniospinal radiother-
apy. Further studies are needed to determine the effectiveness of this sequential combina-
tion of chemotherapy with radiotherapy. © 2016 The Author(s) 
 Published by S. Karger AG, Basel 
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Introduction 
Carcinomatous meningitis, also called ‘neoplastic meningitis’, ‘leptomeningeal carcino-
ma’, or ‘meningeal carcinomatosis’, is a very rare manifestation of metastatic cancer caused 
by the infiltration of cancer cells into the central nervous system through cerebrospinal fluid 
[1]. The diagnosis is confirmed by imaging of the nervous system and cerebrospinal fluid 
analysis. Carcinomatous meningitis in breast cancer occurs as a complication in up to 5% of 
all cases [2]. It is a very devastating diagnosis, with a median patient survival of about 3 
months [2]. The treatment is very controversial. From a literature review, different modali-
ties of treatment have been used, such as intrathecal (IT) and/or systemic chemotherapy 
and radiotherapy, but none of them show significant benefit for overall survival [2]. 
We present 2 patients who have survived for many years after treatment with IT metho-
trexate and subsequent craniospinal radiotherapy. To our knowledge, these are the first 
patients who have survived for that long. 
Case 1 
In October 2000, a 62-year-old with a background of breast cancer was transferred from 
the Neurosciences Unit to the Bristol Oncology Unit with right 7th nerve palsy and numb-
ness with pain affecting the left-sided chest and abdomen. Clinical examination confirmed 
lower motor neuron 7th nerve palsy and altered sensation of the left chest wall and abdo-
men but no clinical evidence of breast cancer recurrence. 
Magnetic resonance imaging (MRI) of the brain and spine did not provide an explana-
tion for her symptoms, but pathological examination of the cerebrospinal fluid revealed nu-
merous malignant cells consistent with carcinomatous meningitis. 
In 1992, the patient was diagnosed with T2 grade 2 intraductal carcinoma, with no 
lymph nodes identified at histology spaceman. No receptors were available at the time of 
diagnosis. Unfortunately, in those years, hormonal receptor status was not a standard prac-
tice, and the patient was put on tamoxifen for 2 years. 
Staging computed tomography (CT) of the chest/abdomen/pelvis showed liver  
haemangiomata, which was also confirmed on ultrasound, without evidence of metastatic 
disease. A bone scan showed a solitary hot spot at the L1 level, which turned out to be de-
generative change. 
On transfer to the Oncology Unit she was comfortable as her pain was controlled with 
morphine and ibuprofen. However, she was very anxious and pessimistic. As a retired mid-
wife, she had some understanding of the implication of her diagnosis. Her performance sta-
tus was 2. 
The most likely diagnosis was localized meningeal recurrence of breast cancer. She was 
commenced on dexamethasone and tamoxifen. Steroids improved her condition so she could 
receive IT methotrexate at a dose of 12.5 mg once weekly over 6 weeks. After a break of 1 
month, she commenced craniospinal radiotherapy – 36 Gy in 20 fractions over 4 weeks. Her 
main symptoms had improved after IT chemotherapy. She tolerated her treatment quite 
well, with no major side effects. 
She was last seen in March 2016 and is due to be seen again in March next year, so she 
has been alive for 17 years since she had been diagnosed with carcinomatous meningitis. At 
the age of 70 years, she was able to walk a mile and dance. Currently, she is 77 and has been 
having some short memory problems, and her mobility is gradually deteriorating. 
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Case 2 
In September 2008, a 43-year-old woman presented to the Emergency Department at 
Frenchay Hospital with a 3-month history of back pain, right hip and knee pain, right leg 
weakness, constipation and urine incontinence, altered sensation in the limbs, and visual 
disturbance with flashing lights in the left eye. Two weeks prior to this admission she was 
seen at Frenchay Hospital with cauda equina symptoms. She has had an MRI of the spine, 
which showed a disc prolapse but did not explain the symptoms. The patient was dis-
charged. However, her pain continued to worsen, and sensation changes progressed across 
the whole of the perianal region. She was unable to sit down for 8 weeks due to pain on flex-
ion and started using a stick as her right leg was weak. 
On examination she had a decreased sensation in the perianal area. Neurological exami-
nation of the upper limbs revealed a slight numbness of the radial side of the forearm. Neu-
rological examination of the lower limbs revealed the following: reduced power in the right 
hip flexion (1/5) and extension (2/5), the power in the left leg was 4/5, absent reflexes in 
both legs, reduced sensation in the right medial aspect of the distal right calf dorsum of the 
foot sole and the lateral dorsum of the left foot and the sole of the left foot. On examination of 
her visual fields, she demonstrated a loss of outer vision in her left eye. 
CT and MRI of the head showed metastases in the right parietal occipital region, togeth-
er with some smaller metastases associated with the dura and skull base (fig. 1). MRI of the 
spine revealed fairly diffuse infiltrating nodules in the nerve roots of the lumbosacral plexus. 
Her performance status was 3 due to progressive leg weakness. 
The diagnosis was meningeal carcinomatosis with brain metastasis from breast cancer. 
No other signs of metastatic breast cancer were seen on CT at this point. 
A year prior to presentation, she had been diagnosed with 4 × 3 cm grade 3 triple-
negative invasive ductal carcinoma treated with 6 cycles of neoadjuvant TAC chemotherapy 
followed by wide local excision and axillary node clearance. None of the 10 lymph nodes 
showed viable cancer. She had also completed radiotherapy to her left breast in May 2008. 
The patient was transferred to our centre and started on inpatient IT methotrexate 12.5 
mg with oral capecitabine. The first 4 cycles of IT methotrexate were administered twice 
weekly due to deteriorating symptoms, as her left leg become weak as well. Her vision im-
proved after 1 cycle of treatment. Other neurological symptoms improved after 3 cycles. 
From that point on she received weekly IT methotrexate. The 6th cycle was delayed by a 
week due to urosepsis and opioid toxicity. Cerebrospinal fluid was sent for analysis by cyto-
spin before each IT treatment. She was discharged on capecitabine (1 week on and 1 week 
off at a 75% dose) before cycle 7 of IT methotrexate. A further cycle of IT methotrexate was 
not given as she was readmitted with pyrexia and pain in her lower abdomen, perianal area, 
and shouting/burning pains down the leg. She did not require any antibiotics, and the pain 
was controlled with analgesia. Her symptoms improved and she received cycle 8 of IT meth-
otrexate as inpatient. In total, she received 8 cycles of IT methotrexate, and her neurological 
symptoms have improved. 
Malignant cells were still present in the cerebrospinal fluid. MRI of the head and spine 
after IT chemotherapy combined with capecitabine showed good response to therapy with 
disappearance of some of the smaller metastatic lesions and a significant reduction in the 
size of the larger lesions in the brain, but the spine lesions within the theca were more prom-
inent, suggesting progressive disease. 
She was referred for craniospinal radiotherapy and started 10 days after her last IT 
treatment. She received 36 Gy in 20 fractions over 4 weeks. MRI of the head/spine after ra-
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diotherapy showed significant improvement in the appearances of both intracerebral and 
ependymal metastases. 
In April 2009, MRI of the head showed further involution of cerebral metastases. The 
posterior fossa and right frontal metastases were essentially invisible, while the right occipi-
tal metastases in the lobe showed further involution. There was no convincing focal menin-
geal mass. She was treated with carboplatin 6 months after completion of craniospinal radio-
therapy to prevent recurrence of meningeal disease. She completed 4 cycles of carboplatin 
between 21/05/2009 and 10/09/2009. 
In 2011, she had recurrent solitary right occipital metastasis, which was treated with 
stereotactic radiotherapy. In 2012, MRI showed increasing occipital abnormality with oede-
ma, which was surgically excised and proved to be radiation necrosis only, with no viable 
tumour. In 2013, MRI showed no new disease, only post-surgical changes (fig. 2). 
It has been 8 years since she first presented with neurological symptoms. Currently, the 
patient is in complete clinical and radiological remission and has recently been discharged 
from our clinic. 
Discussion 
We present 2 patients with a history of breast cancer who developed meningeal carci-
nomatosis with no evidence of metastatic visceral disease. Both patients were treated with 
IT methotrexate and subsequent craniospinal radiotherapy. The second patient has had fur-
ther treatment for brain metastasis and also received concomitant oral capecitabine with IT 
methotrexate. The first patient is still alive after 17 years and the second patient 8 years 
after primary treatment. To our knowledge, there are no patients in the literature who have 
survived that long after meningeal carcinomatosis diagnosis. 
Still, treatment remains controversial. There are National Comprehensive Cancer Net-
work (NCCN) guidelines how to treat meningeal disease according to ‘poor-risk’ and ‘good-
risk’ groups. Many patients will fall in between these two groups. Clinical judgment normally 
dictates how intensive the treatment should be. The recommendation for the ‘poor-risk’ 
group is supportive care. External beam radiotherapy can be considered for symptomatic 
sites. The options for ‘good-risk’ patients and those with breast cancer are IT chemotherapy, 
high-dose methotrexate, or craniospinal radiotherapy [3]. 
In the literature, there is various evidence of different types of treatments, such as sys-
temic chemotherapy of capecitabine, eribulin as a single treatment, or combined with IT 
chemotherapy using methotrexate, topotecan, thiothepa, and liposomal cytarabine. There 
are also some reports of using craniospinal radiotherapy. Overall survival in those studies 
was counted in months [2, 4–8]. 
We can conclude that isolated meningeal metastasis from breast cancer can potentially 
be very effectively treated with combined IT and/or systemic chemotherapy followed by 
craniospinal radiotherapy. Further studies are needed to determine the effectiveness of this 
combined treatment of chemotherapy with radiotherapy. 
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Fig. 1. MRI of the patient’s head at diagnosis in the year 2008. Metastatic lesion in the right occipital region 
is shown. 
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Fig. 2. MRI of the patient’s head in 2013. Post-surgical change in the right occipital region is shown. 
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